Muscari 2001.

Methods	Participants did not receive lipid‐lowering drugs for 3 months before randomisation 3‐Month randomised double‐blind placebo‐controlled trial
Participants	60 men aged 55 to 64 years with C3 > 1.19 g/L, TC ≥ 5.56 mmol/L Exclusion criteria: none reported Placebo: Baseline TC: 6.68 mmol/L (258 mg/dL) Baseline HDL‐C: 1.35 mmol/L (52 mg/dL) Atorvastatin: Baseline TC: 6.47 mmol/L (250 mg/dL) Baseline HDL‐C: 1.36 mmol/L (53 mg/dL)
Interventions	Placebo for vitamin E low cholesterol Vitamin E low cholesterol Placebo for atorvastatin high cholesterol Atorvastatin 10 mg/d high cholesterol Atorvastatin 10 mg/d + vitamin E high cholesterol
Outcomes	% change from baseline of TC and HDL‐C
Notes	Placebo for atorvastatin high cholesterol and atorvastatin 10 mg/d high cholesterol were analysed SDs were imputed WDAEs were not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information about sequence generation was provided to permit judgement of 'yes' or 'no'
Allocation concealment (selection bias)	Unclear risk	No information about allocation concealment was provided to permit judgement of 'yes' or 'no'
Blinding (performance bias and detection bias) All outcomes	Low risk	"Double‐blindly"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	3/30 participants who received atorvastatin only were not analysed (10%); some bias is possible
Selective reporting (reporting bias)	High risk	LDL‐C and TG data were not reported; WDAEs were not reported
Other bias	Low risk	The study appears to be free of other sources of bias